Relapsing Forms of Multiple Sclerosis: Clinical Trials

2 completed, 1 not yet recruiting, 1 withdrawn. 4 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	4	Completed 2, Not yet recruiting 1, Withdrawn 1

Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis	Phase 3	Not yet recruiting	Biogen	185	2026-11-16	2026-03-19
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel fumarate - Relapsing Forms of Multiple Sclerosis	Phase 3	Completed	Biogen	136	2021-11-18	2025-10-24
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) dimethyl fumarate, Placebo - Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis	Phase 3	Withdrawn	Biogen		2016-05-01	2016-04-13
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod - Relapsing Forms of Multiple Sclerosis	Phase 3	Completed	Novartis Pharmaceuticals	4125	2010-09-13	2021-04-21

Narrower conditions

Multiple Sclerosis (2)  ·  Multiple Sclerosis, Relapsing-Remitting (1)

Broader conditions

Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Demyelinating Autoimmune Diseases, CNS (2)  ·  Demyelinating Diseases (2)  ·  Immune System Diseases (2)  ·  Nervous System Diseases (2)

Interventions

Dimethyl Fumarate (2)  ·  Fingolimod Hydrochloride (2)  ·  diroximel fumarate (2)

Sponsors

Biogen (3)  ·  Novartis Pharmaceuticals (1)

Countries

Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Egypt (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)

Results publications

PMID 31598139

NIH funding

2014 (1), 2023 (1)